Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Clinical Benefits of Achieving Deep Remission to Second-Line Therapy in Patients with Relapse/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) - a Real-World Study

William G Wierda, MD PhD, Genevieve Gauthier, MSc, Brian Meissner, PharmD, PhD, Annie Guerin, MS, Jennifer C. Samp, MS, PharmD

Blood (2017) 130 (Supplement 1): 2130.

https://doi.org/10.1182/blood.V130.Suppl_1.2130.2130

Published: 2017

Journal Articles

Drivers of Treatment Patterns in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with B-Cell Receptor Inhibitors (BCRis) — a Medical Chart Review Study

Anthony R. Mato, MD, Jennifer C. Samp, MS, PharmD, Genevieve Gauthier, MSc, Emi Terasawa, PhD, Danielle M. Brander, MD

Blood (2017) 130 (Supplement 1): 4681.

https://doi.org/10.1182/blood.V130.Suppl_1.4681.4681

Published: 2017

Journal Articles

Short-Term and Long-Term Economic Burden Following Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in Adult Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Richard T. Maziarz, MD, Yanni Hao, PhD, Annie Guerin, MSc, Genevieve Gauthier, MSc, Marjolaine Gauthier-Loiselle, PhD, Simu K Thomas, PhD, Lamis K Eldjerou, MD

Blood (2016) 128 (22): 5933.

https://doi.org/10.1182/blood.V128.22.5933.5933

Published: 2016

Journal Articles

The Healthcare Resource Utilization, Costs, and Predictors of Progression Among Relapsed and Refractory CLL Patients

Annie Guerin, MSc, Saurabh Ray, PhD, Genevieve Gauthier, MSc, Ling-I Hsu, PhD, Maryia Zhdanava, Eric Wu, PhD

Blood (2015) 126 (23): 3313.

https://doi.org/10.1182/blood.V126.23.3313.3313

Published: 2015

Journal Articles

Five-Year Direct Cost of Pediatric Patients with Acute Lymphoblastic Leukemia (ALL) Undergoing Allogeneic Stem Cell Transplantation (HSCT): An Analysis from US Payers' Perspective

Richard T. Maziarz, MD, Annie Guerin, MSc, Genevieve Gauthier, MSc, Julie Heroux, MSc, Maryia Zhdanava, MSc, Eric Q Wu, PhD, Simu K Thomas, PhD, Lei Chen, MDPhD

Blood (2015) 126 (23): 872.

https://doi.org/10.1182/blood.V126.23.872.872

Published: 2015

NARROW

Clinical Benefits of Achieving Deep Remission to Second-Line Therapy in Patients with Relapse/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) - a Real-World Study

Drivers of Treatment Patterns in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with B-Cell Receptor Inhibitors (BCRis) — a Medical Chart Review Study

Short-Term and Long-Term Economic Burden Following Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in Adult Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

The Healthcare Resource Utilization, Costs, and Predictors of Progression Among Relapsed and Refractory CLL Patients

Five-Year Direct Cost of Pediatric Patients with Acute Lymphoblastic Leukemia (ALL) Undergoing Allogeneic Stem Cell Transplantation (HSCT): An Analysis from US Payers' Perspective

Email alerts

ASH Publications

American Society of Hematology

Clinical Benefits of Achieving Deep Remission to Second-Line Therapy in Patients with Relapse/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) - a Real-World Study

Drivers of Treatment Patterns in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with B-Cell Receptor Inhibitors (BCRis) — a Medical Chart Review Study

Short-Term and Long-Term Economic Burden Following Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in Adult Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

The Healthcare Resource Utilization, Costs, and Predictors of Progression Among Relapsed and Refractory CLL Patients

Five-Year Direct Cost of Pediatric Patients with Acute Lymphoblastic Leukemia (ALL) Undergoing Allogeneic Stem Cell Transplantation (HSCT): An Analysis from US Payers' Perspective

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only